n | 695 |
---|---|
Female/male, n (%) | 457 (66)/238 (34) |
Median; IQR | |
Age at diagnosis, years | 6.5; 3.0–11.3 |
Age at study enrolment, years | 6.9; 3.2–11.6 |
Time from symptom onset to diagnosis, months | 3.0; 1.0–6.0 |
Time from diagnosis to enrolment, months | 1.6; 0.4–4.6 |
JIA categories | n/% |
OA | 313/45.0 |
Polyarthritis RF negative (RF– PA) | 195/28.1 |
Polyarthritis RF positive (RF+ PA) | 10/1.4 |
PsA | 28/4.0 |
ERA | 74/10.7 |
soJIA | 25/3.6 |
UA | 50/7.2 |
n/% tested | |
ANA positive | 393/59.1 |
RF positive | 21/3.8 |
HLA-B27 positive | 106/20.1 |
ANA, antinuclear antibodies; ERA, enthesitis-related arthritis; HLA, human leucocyte antigen; JIA, juvenile idiopathic arthritis; OA, oligoarthritis; PsA, Psoriatic arthritis; RF, rheumatoid factor; soJIA, systemic-onset JIA; UA, undifferentiated arthritis.